Abstract:Introduction: To identify the absolute risk of specific HPV genotype for cervical intraepithelial neoplasia grade 2/3 or worse (CIN2/3+) and form the risk-based management strategy by extended HPV genotyping in HPV positive population.Methods: HPV genotyping was performed based on 3-years cervical cancer screening cohort including 10314 women from 2 clinical trials. The study endpoints were histological CIN2+/3+. The prevalence of specific HPV genotype was calculated by minimum estimate, any type estimate and hierarchical attribution estimate. The absolute CIN2+/3+ risks of specific HPV genotype, cytology and combined test were estimated and risk-based management strategy was established according to ASCCP guideline. The performance of conventional and risk-based management strategies for non-16/18 HPVs to detect CIN2+/3+ were further evaluated.Findings: Eligible data were available for 8370 women with median age of 48 (IQR 42-53). At baseline, HPV positive women were 1062, including 424 multiple infections and 639 single infections. CIN2+/3+ cases were 113/74, 23/8, 20/7 and 52/31 at baseline, the 1st, 2nd and 3rd year of visit. Women with multiple HPV infections at baseline were prone to persistent infection than single infection (p<0.0001). HPV16 and 52 were top two ranking among baseline and 3-years cumulative CIN2+/3+ cases. Based on the absolute risk of specific HPV genotype combined with cytology for CIN2+/3+, all non-16/18 HPVs were divided into 4 risk stratified groups. Compared to conventional strategy, the risk-based strategies had higher specificity (p=0.0000) and PPV (p=0.0322) to detect CIN3+, and needed fewer colposcopies for each CIN3+ case.Interpretation: We proposed a new extended HPV genotyping protocol based on the absolute risk of specific HPV genotype, and corresponding management thresholds were suggested for achieving the precise risk-based management of HPV positive population.Funding Information: Supported by the key research and development program of Zhejiang province, China (Grant No: 2020C03025).Declaration of Interests: All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.Ethics Approval Statement: The study was approved by the Ethics Committee of Women’s Hospital, Zhejiang University School of Medicine (IRB-20200240-R). Informed consent was obtained for clinical trial.

Structural Basis for the Shared Neutralization Mechanism of Three Classes of Human Papillomavirus Type 58 Antibodies with Disparate Modes of Binding

Human Papillomavirus Isolated from Multiple Infections of Female Genitourinary Tract and Its Subtype Detections

Human papillomavirus type 58 genome variations and RNA expression in cervical lesions.

Human papillomavirus prevalence and type-distribution among women in Zhejiang Province, Southeast China: a cross-sectional study

Multiple human papillomavirus infections and type-competition in women from a clinic attendee population in China.

The Study of Human Papillomavirus Genotyping in Cervical Cancer

Distribution of Human Papillomavirus Genotypes in the Patients with Cervical Carcinoma and Its Precursors in Zhejiang Province, China

Phylogeographic Analysis of Human Papillomavirus 58

Potent Neutralizing Humanized Antibody with Topical Therapeutic Potential Against HPV18-Related Cervical Cancer

Prevalence of High-Risk Human Papillomavirus and Cervical Lesion Risk Factors: A Population-Based Study in Zhejiang, China 2010-2019

Induction of Co-Inhibitory Molecule CTLA-4 by Human Papillomavirus E7 Protein Through Downregulation of Histone Methyltransferase JHDM1B Expression

Genetic variability of E6 and E7 genes of human papillomavirus type 58 in Jingzhou, Hubei Province of central China

Identification of the mimotopes within the major capsid protein L1 of human papillomavirus types 18 and 45, using neutralizing monoclonal antibodies

Detection of human papillomavirus genotypes in cervical carcinoma and intraepithelial neoplasia.

Extended Human Papilloma Virus Genotyping for Risk Assessment of Cervical Intraepithelial Neoplasia Grade 2 or Worse in a Cohort Study

Genetic variability analysis of human papillomavirus 58: Novel sublineage identification and persistent infection association

Characterization of a triple-type chimeric vaccine against human papillomavirus types 18, 45, and 59

High-Risk Genotypes of Human Papillomavirus at Diverse Anogenital Sites among Chinese Women: Infection Features and Potential Correlation with Cervical Intraepithelial Neoplasia

Whole-Genome Analysis of Human Papillomavirus Types 16, 18, and 58 Isolated from Cervical Precancer and Cancer Samples in Chinese Women

Global evaluation of lineage-specific human papillomavirus capsid antigenicity using antibodies elicited by natural infection

Unique variants of human papillomavirus genotypes 52 and 58 and risk of cervical neoplasia